Mark Wickham Email & Phone Number

Cambridge, United Kingdom

Alacramed was formed as a spin-out from leading lifescience biopharma consultancy Alacrita. Spinning out a separate business was a strategic move to enhance focus on medical devices and better serve Alacrita's growing number of medical device clients. We understood that medtech often has diverse and very different challenges to biopharma and that to meet.

Cambridge, United Kingdom

I mentor teams of students at the Judge Institute, the University of Cambridge's business school, in addressing real problems set by medical technology companies. The projects have real value to the companies and the output is often used to guide their strategy.

London, United Kingdom

Mark was the medical device consulting Partner at leading life science consultancy Alacrita Consulting Ltd. As a managing partner he was responsible for the pipeline of medical device consulting projects. This involved both business development, and the management and operation of projects than spanned most aspects of commercialising medical device.

Cambridge, United Kingdom

At PA Mark consulted in the medical device industry sector in Europe and the USA. He focused especially on the commercial exploitation of new technologies winning and leading assignments ranging from developing new products to finding new commercial opportunities for existing technologies.

Aberdeen, United Kingdom

As CEO of this VC-funded orthopaedic company, Mark’s role focused on business planning, raising venture funding and securing industry licensing deals (licensing deals were completed with two major companies). B1 had exclusive pipeline IP agreements with The University of Aberdeen, NHS Grampian and Robert Gordon University.

York, United Kingdom

Mark had management responsibility for a fully autonomous R&D site of 170 staff that included 60 PhD level technologists. Functional responsibility also covered Finance, Human Resources, IT, Public Relations, and Legal and Patent support. The site encompassed a pre-clinical unit and a clean room for pilot manufacture. He spearheaded corporate venturing.

Cambridge, United Kingdom

Mark founded the company with colleagues to develop a novel pressure meter dose inhaler valve design that he invented. As CEO, he led the development of the business plan and initiated negotiations at Main Board level with a number of major healthcare companies. The IP was successfully out-licensed for commercialisation to a leading respiratory drug.

Kings Lynn, United Kingdom

Mark led the product development function at Bespak delivering five new injection moulded respiratory drug delivery products through to product launch. Other achievements included: developing the company’s IP strategy; playing a leading role in initiating a number of strategic collaborations and in-licensing novel drug delivery formulations; leading a.

Cambridge, United Kingdom

Responsible for the general management of medical device and consumer product company LIG’s central R&D laboratories which included 70 professional staff, four laboratories and IT/administrative services. Responsibilities also included: the preparation of R&D’s rolling three year business plan; the implementation of LIG’s strategy of creating competitive.

Melbourn, United Kingdom

At TTP Mark focused on developing consultancy business in Europe and the USA primarily in medical technologies. In addition he initiated the internal development of a novel diagnostic system for the continuous measurement of blood gases and led funding and licensing discussions with potential collaborating companies.

Abingdon, United Kingdom

In the UK Mark managed a team of ten scientists and engineers. He was part of the team that developed ‘ExacTech’ the world’s first electrochemical blood glucose test. This product is now marketed worldwide by Abbott Laboratories.In the USA Mark set-up the Company’s US laboratory and recruited a team of scientists and engineers to develop a novel in-vivo.

Mba

Phd, Polymer Chemistry

Bsc, Chemistry